RecruitingPhase 2NCT03737955

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Studying Acute monoblastic/monocytic leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Washington
Principal Investigator
Mary-Elizabeth Percival, M.D
Fred Hutch/University of Washington Cancer Consortium
Intervention
Gemtuzumab Ozogamicin(drug)
Enrollment
36 enrolled
Eligibility
18 years · All sexes
Timeline
2018 – 2026

Study locations (1)

Collaborators

Pfizer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03737955 on ClinicalTrials.gov

Other trials for Acute monoblastic/monocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute monoblastic/monocytic leukemia →

← Back to all trials